Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Dermatologic 5Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Lymphoid 1Classical hematology 1Breast 1

Conditions

Lymphoma 1Inflammatory Bowel Diseases 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

Rituximab 1371Cyclophosphamide 1296Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 461Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 254ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 227Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infliximab × Lymphoid × Clear all
NCT01804166 2025-02-04

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

Janssen Scientific Affairs, LLC

Phase 4 Completed
1 enrolled 1 chart
Lymphoid

Colitis, Ulcerative, Crohn Disease, Lymphoma, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡